Jacobs Levy Equity Management’s 10x Genomics TXG Stock Holding History

Jacobs Levy Equity Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77.4M	Sell	2,019,883 -263,541	-12%	-$6.91M	0.28%	95
2026 Q1	$48.5M	Sell	2,283,424 -356,575	-14%	-$7.13M	0.2%	118
2025 Q4	$43.1M	Sell	2,639,999 -307,990	-10%	-$4.65M	0.17%	125
2025 Q3	$34.5M	Buy	2,947,989 +550,250	+23%	+$7.17M	0.14%	145
2025 Q2	$27.8M	Buy	2,397,739 +1,231,016	+106%	+$11.2M	0.11%	177
2025 Q1	$10.2M	Buy	1,166,723 +1,135,356	+3,620%	+$14.3M	0.04%	336
2024 Q4	$450K	Buy	+31,367	New	+$495K	﹤0.01%	825
2024 Q3	–	Sell	-101,301	Closed	-$1.97M	–	1052
2024 Q2	$1.97M	Buy	101,301 +4,129	+4%	+$108K	0.01%	597
2024 Q1	$3.65M	Buy	+97,172	New	+$4.27M	0.02%	486

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jacobs Levy Equity Management's TXG Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its 10x Genomics (TXG) stake by 12% in Q2 2026, selling an estimated $6.91M and leaving 2,019,883 shares worth $77.4M. The position accounts for 0.28% of the portfolio, ranked #95.

Jacobs Levy Equity Management first reported a position in TXG in Q1 2024 and has held it in 9 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Jacobs Levy Equity Management held 2,019,883 shares of 10x Genomics worth $77.4M as of Q2 2026.
Jacobs Levy Equity Management sold 263,541 10x Genomics shares in Q2 2026, an estimated $6.91M.
10x Genomics made up 0.28% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #95 holding.
Jacobs Levy Equity Management first reported a position in 10x Genomics in Q1 2024 and has held it in 9 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.